{
  "id": 16886503,
  "title": "Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight loss",
  "url": "https://urgent.news/2026/10/28/bye-bye-ozempic-eli-lilly-says-its-new-drug-retatrutide-more-than",
  "topic": "business",
  "section": "Business",
  "published": "2026-10-28T10:45:01.000Z",
  "source": {
    "name": "Business Insider",
    "slug": "business-insider",
    "url": "https://www.businessinsider.com/retatrutide-ozempic-weight-loss-comparison-side-effects-eli-lilly-results-2026-10"
  },
  "original_language": "en",
  "account": "Ozempic's rival, retatrutide, is a more potent weight-loss drug developed by Eli Lilly. In a clinical trial, retatrutide users lost roughly twice as much weight compared to those taking Ozempic. The trial results showed that Ozempic users on the highest dose lost an average of 21 pounds over a year and a half, while retatrutide users lost an average of 44 to 47 pounds during the same period. Retatrutide has the potential to change the treatment paradigm for type 2 diabetes, obesity, and related cardiometabolic conditions. The drug is still in clinical development and has not received FDA approval yet. Some peptide sellers are illegally selling a knock-off version of retatrutide, which is referred to as 'reta'. The FDA is expected to review and approve retatrutide in early 2027, potentially making it available for obesity, sleep apnea, and knee osteoarthritis.",
  "summary": "In the first head-to-head trial of Ozempic versus Eli Lilly's new \"King Kong\" drug retatrutide, the next-generation drug led to more weight loss.",
  "key_points": [
    "Retatrutide more than doubles Ozempic weight loss in clinical trial",
    "Ozempic users lost 21 pounds on highest dose, retatrutide users lost 44-47 pounds",
    "Retatrutide expected FDA approval in early 2027"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}